about
Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacinA New Crystal Structure of the Bifunctional Antibiotic Simocyclinone D8 Bound to DNA Gyrase Gives Fresh Insight into the Mechanism of InhibitionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionQuinolone-induced upregulation of osteopontin gene promoter activity in human lung epithelial cell line A549.Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth.Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits.Magnetic Nanoparticles for Antibiotics Detection.A Novel Chimeric Endolysin with Antibacterial Activity against Methicillin-Resistant Staphylococcus aureus.Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.Modification of norfloxacin by a Microbacterium sp. strain isolated from a wastewater treatment plant.Prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-nonsusceptible Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in KoreaSafety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.Prulifloxacin: a new antibacterial fluoroquinolone.Characterization of plasmid-mediated quinolone resistance (PMQR) genes in extended-spectrum β-lactamase-producing Enterobacteriaceae pediatric clinical isolates in Mexico.Effect of on-farm use of antimicrobial drugs on resistance in fecal Escherichia coli of preweaned dairy calves.A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India.Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individualsAssessing the antibiotic susceptibility of freshwater Cyanobacteria sppThe influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.Levofloxacin for the treatment of community-acquired pneumonia.Synthesis, Antibacterial Evaluation and QSAR of α-Substituted-N₄-Acetamides of Ciprofloxacin and Norfloxacin.Induction of plasmid-carried qnrS1 in Escherichia coli by naturally occurring quinolones and quorum-sensing signal molecules.Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Antituberculosis drug research: a critical overview.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.Microbial transformations of antimicrobial quinolones and related drugs.Efficacy of Triple Antibiotic Paste, Moxifloxacin, Calcium Hydroxide And 2% Chlorhexidine Gel In Elimination of E. Faecalis: An In vitro Study.Synthesis of N-substituted 2-[(1E)-alkenyl]-4-(1H)-quinolone derivatives as antimycobacterial agents against non-tubercular mycobacteria.Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study.Factors Affecting Penetration of Ciprofloxacin in Lower Extremity Ischemic Tissues.(68) Ga-labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection.SimC7 Is a Novel NAD(P)H-Dependent Ketoreductase Essential for the Antibiotic Activity of the DNA Gyrase Inhibitor Simocyclinone.Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinCrystal structures of [Mn(bdc)(Hspar)2(H2O)0.25]·2H2O containing MnO6+1 capped trigonal prisms and [Cu(Hspar)2](bdc)·2H2O containing CuO4 squares (Hspar = sparfloxacin and bdc = benzene-1,4-di-carboxyl-ate).
P2860
Q26746616-EEABC2E6-F93D-44EA-9B88-BDD5ECC106EBQ27681978-EE848572-E8F9-4343-94FF-DFD6B2C42BF8Q28084026-1FD0103C-6EDF-4065-B7A5-7C7936857F84Q30394542-637A8C33-0D4A-4C84-B258-F11141219206Q33295385-65145DB3-2D31-4703-B972-549075F81E4BQ33593726-6CDE9169-C35A-45C4-97BC-D4232DC3DB5DQ33837829-A3A8077C-BF6F-4868-B3CC-359C7F16AFC6Q33854421-3F5BC583-C82C-4169-A303-5E75CB192E0BQ33893117-DB3011E4-8DA0-44CF-ADFB-AC33987781C4Q33949396-9F66DDD0-1AEC-4298-9DAC-C03737E2BD89Q34238560-2DF0C155-CE66-4E5B-819C-228BFEC06142Q34278283-D4355EAD-0BBF-46F8-A8C3-F76171362C1EQ34298845-F377C9A2-647D-4BA4-BD10-8363C8FD9520Q34564526-C79B11D9-5CC5-40A0-A427-A1CA54FDBCFAQ35023502-9F6ACBFB-FD5C-4FB6-89B6-A6B06DDEC619Q35154025-9133010B-CE5C-4530-903F-4063D02AA62CQ35686847-3DEB889E-C99E-43D2-A22C-27B479487BB6Q35844592-9F8E7430-5808-43CD-BCF4-BCF77B9AB166Q35935941-58B3E6CE-D0CA-4ABA-9656-660201991DF0Q36379846-158445C5-F793-4A8A-BA67-E688FE44AC61Q36670872-30EE3FDF-9748-4544-80C4-55E41EC54A35Q36683640-D0ED5B68-B907-4D99-A3AB-7F3774A98CBDQ37036595-7E0E8D60-D4B3-4293-BDEB-BB47992E9AF6Q37190660-C3E26615-B263-45FE-98C8-7D16B1E66A4FQ37409945-A75FA898-2556-4FCD-AA04-2B13028FC702Q37544479-26A94B23-0F40-4B9D-AE0B-47DC7BEE64F9Q37710230-BE8E8075-5C1A-4165-8DE4-6CA4E93614C3Q37982661-8739B03A-6190-4B4C-8271-E02C603B2FD3Q38012651-2A2E376E-C893-42A5-9A0F-4E274E8308EDQ38040734-54D85075-400F-43C9-9D05-030274162123Q38046140-AA0E966F-BA94-470A-9B70-B4ED26AC05AFQ38920378-54A0AE80-B96F-445A-AF84-FA50A569B463Q39571968-F3FC5239-482E-4675-AE77-58DFDF86623FQ40117762-2E14E5FA-042F-46A9-A62E-DD41829293D8Q40164488-6699659E-C55A-4B82-A080-C464C4DA7A60Q40878782-69207695-3929-4677-BF38-EC2F4C4DC38AQ41518213-05A97654-039B-4D7D-9098-A7F2E2FF2353Q41534755-B1BFD82A-35F8-4728-A459-CF20668F3D0FQ42078632-1D800046-926F-4FA6-8C02-7AE0E8FF07BFQ43101007-1BDDF88E-013A-40E9-AE11-0BFC03415B35
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development of the quinolones.
@ast
Development of the quinolones.
@en
type
label
Development of the quinolones.
@ast
Development of the quinolones.
@en
prefLabel
Development of the quinolones.
@ast
Development of the quinolones.
@en
P356
P1476
Development of the quinolones.
@en
P2093
Alasdair P MacGowan
Monique I Andersson
P356
10.1093/JAC/DKG212
P407
P478
51 Suppl 1
P577
2003-05-01T00:00:00Z